These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28784284)

  • 1. Key points in evaluating immunogenicity of pandemic influenza vaccines: A lesson from immunogenicity studies of influenza A(H1N1)pdm09 vaccine.
    Ohfuji S; Kobayashi M; Ide Y; Egawa Y; Saito T; Kondo K; Ito K; Kase T; Maeda A; Fukushima W; Hirota Y
    Vaccine; 2017 Sep; 35(39):5303-5308. PubMed ID: 28784284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study.
    Kang EK; Eun BW; Kim NH; Lim JS; Lee JA; Kim DH
    BMC Infect Dis; 2016 Aug; 16(1):438. PubMed ID: 27549626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of influenza A(H1N1)pdm09 vaccine and the associated factors on lowered immune response in patients with hepatitis C.
    Ohfuji S; Fukushima W; Tamori A; Maeda K; Maeda A; Hirota Y
    Influenza Other Respir Viruses; 2013 May; 7(3):456-65. PubMed ID: 22897938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host immune response to A(H1N1)pdm09 vaccination and infection: a one-year prospective study on six cohorts of subjects.
    Liu W; Ma MJ; Tang F; He C; Zhang XA; Jiang LF; Xin DS; Hu CY; Looman C; Cao WC
    Vaccine; 2012 Jul; 30(32):4785-9. PubMed ID: 22633868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
    Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
    Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.
    Ottóffy G; Horváth P; Muth L; Sólyom A; Garami M; Kovács G; Nyári T; Molnár D; Pauler G; Jankovics I
    Pediatr Blood Cancer; 2014 Jun; 61(6):1013-6. PubMed ID: 24395342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
    Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
    Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: systematic review and meta-analyses.
    Yin JK; Chow MY; Khandaker G; King C; Richmond P; Heron L; Booy R
    Vaccine; 2012 May; 30(21):3209-22. PubMed ID: 22387221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine.
    Gaglani M; Spencer S; Ball S; Song J; Naleway A; Henkle E; Bozeman S; Reynolds S; Sessions W; Hancock K; Thompson M
    J Infect Dis; 2014 Jun; 209(11):1705-14. PubMed ID: 24363436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season.
    Bateman AC; Kieke BA; Irving SA; Meece JK; Shay DK; Belongia EA
    J Infect Dis; 2013 Apr; 207(8):1262-9. PubMed ID: 23341536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody persistence 1 year after pandemic H1N1 2009 influenza vaccination and immunogenicity of subsequent seasonal influenza vaccine among adult organ transplant patients.
    Felldin M; Andersson B; Studahl M; Svennerholm B; Friman V
    Transpl Int; 2014 Feb; 27(2):197-203. PubMed ID: 24289658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic.
    Chuaychoo B; Kositanont U; Rittayamai N; Niyomthong P; Songserm T; Maranetra KN; Rattanasaengloet K; Nana A
    Hum Vaccin Immunother; 2016 Jul; 12(7):1728-37. PubMed ID: 27153158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-reactive antibody response to the pandemic A (H1N1) 2009 influenza virus induced by vaccination with a seasonal trivalent influenza vaccine: a longitudinal study of three influenza seasons in Japan.
    Uno S; Kimachi K; Matsuo F; Miyazaki K; Oohama A; Kei J; Nishimura T; Odoh K; Kino Y
    Microbiol Immunol; 2012 Dec; 56(12):810-6. PubMed ID: 23009167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Large Proportion of the Mexican Population Remained Susceptible to A(H1N1)pdm09 Infection One Year after the Emergence of 2009 Influenza Pandemic.
    Veguilla V; López-Gatell H; López-Martínez I; Aparicio-Antonio R; Barrera-Badillo G; Rojo-Medina J; Gross FL; Jefferson SN; Katz JM; Hernández-Ávila M; Alpuche-Aranda CM
    PLoS One; 2016; 11(3):e0150428. PubMed ID: 27003409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation.
    Lagler H; Tobudic S; Ramharter M; Elandt K; Sperr WR; Redlberger-Fritz M; Popow-Kraupp T; Jäger U; Zielinski CC; Burgmann H
    Vaccine; 2012 Nov; 30(48):6864-70. PubMed ID: 22989690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvanted influenza a (H1N1) 2009 vaccine in patients with hematological diseases: good safety and immunogenicity even in chemotherapy-treated patients.
    Cherif H; Höglund M; Pauksens K
    Eur J Haematol; 2013 May; 90(5):413-9. PubMed ID: 23444982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany.
    Cramer J; Mac T; Hogan B; Stauga S; Eberhardt S; Wichmann O; Mertens T; Burchard G
    Euro Surveill; 2012 Jan; 17(2):. PubMed ID: 22264864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial.
    Vajo Z; Tamas F; Sinka L; Jankovics I
    Lancet; 2010 Jan; 375(9708):49-55. PubMed ID: 20018367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children.
    Örtqvist Å; Bennet R; Hamrin J; Rinder MR; Lindblad H; Öhd JN; Eriksson M
    Vaccine; 2015 May; 33(22):2558-61. PubMed ID: 25869891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.